Skip to main content
SpringerLink
Log in

Moxifloxacin

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Moxifloxacin is a new fluoroquinolone antibacterial agent with a broad spectrum of activity, encompassing Gram-negative and Gram-positive bacteria. It has improved activity against Gram-positive species (including staphylococci, streptococci, enterococci) and anaerobes compared with ciprofloxacin. This is offset by slightly lower activity against pseudomonal species and Enterobacteriaceae.

  • ▴ In common with other fluoroquinolones, moxifloxacin attains good penetration into respiratory tissues and fluids and its bioavailability is substantially reduced by coadministration with an antacid or iron preparation. However, moxifloxacin does not interact with theophylline or warfarin.

  • ▴ In clinical trials in patients with community-acquired pneumococcal pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB) or acute sinusitis, moxifloxacin 400mg once daily achieved bacteriological and/or clinical success rates of approximately 90% or higher.

  • ▴ Moxifloxacin was as effective as amoxicillin 1g 3 times daily and clarithromycin 500mg twice daily in CAP and as effective as clarithromycin in AECB. In patients with sinusitis, a 7-day course of moxifloxacin 400mg once daily was as effective as a 10-day course of cefuroxime axetil 250mg twice daily.

  • ▴ In contrast to some other fluoroquinolones, moxifloxacin appears to have a low propensity for causing phototoxic and CNS excitatory effects. The most common adverse events are gastrointestinal disturbances.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639–51

    Article  PubMed  CAS  Google Scholar 

  2. Krasemann C, Meyer JM, Springsklee M. Suggested breakpoints for moxifloxacin (MXF). Poster (#PO206) accepted by 9th ECCMID; 1999 Mar 21–24; Berlin

  3. Fass RJ. In. vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother 1997 Aug; 41: 1818–24

    PubMed  CAS  Google Scholar 

  4. Schülin T, Wennersten CB, Ferraro MJ, et al. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998 Jun; 42: 1520–3

    PubMed  Google Scholar 

  5. Bébéar CM, Renaudin H, Boudjadja A, et al. In vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas. Antimicrob Agents Chemother 1998 Mar; 42: 703–4

    Article  PubMed  Google Scholar 

  6. Ruckdeschel G, Lob S. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Legionella spp. in comparison to ciprofloxacin, erythromycin and rifampicin [abstract]. 36th ICAAC; 1996 Sep 15; New Orleans, 101

  7. Roblin PM, Hammerschlag MR. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998 Apr; 42: 951–2

    PubMed  CAS  Google Scholar 

  8. Biedenbach DJ, Barrett MS, Croco MAT, et al. BAY 12-8039, a novel fluoroquinolone: activity against important respiratory tract pathogens. Diagn Microbiol Infect Dis 1998 Sep; 32: 45–50

    Article  PubMed  CAS  Google Scholar 

  9. Weiss K, Laverdiere M, Restieri C. Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother 1998 Oct; 42: 523–5

    Article  PubMed  CAS  Google Scholar 

  10. Klugman KP, Capper T. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin. J Antimicrob Chemother 1997 Dec; 40: 797–802

    Article  PubMed  CAS  Google Scholar 

  11. Ji B, Lounis N, Maslo C, et al. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998 Aug; 42: 2066–9

    PubMed  CAS  Google Scholar 

  12. Aldridge KE, Ashcraft DS. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997 Mar; 41: 709–11

    PubMed  CAS  Google Scholar 

  13. Edlund C, Sabouri S, Nord CE. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis 1998 Mar; 17: 193–5

    Article  PubMed  CAS  Google Scholar 

  14. Woodcock JM, Andrews JM, Boswell FJ, et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997 Jan; 41: 101–6

    PubMed  CAS  Google Scholar 

  15. Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of BAY 12-8039 on Gram-positive and Gram-negative organisms as demonstrated by studies of time-kill kinetics and post-antibiotic effect. Antimicrob Agents Chemother 1997 Jun; 41: 1377–9

    PubMed  CAS  Google Scholar 

  16. Al-Nawas B, Shah PM. Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1998 Jun; 41: 655–8

    Article  PubMed  CAS  Google Scholar 

  17. Davidson RJ, Fuller J, Low DE. Pharmacodynamic properties of moxifloxacin, levofloxacin, and clarithromycin in S. pneumoniae and H. influenzae [abstract]. 38th ICAAC; Sep 24; San Diego; 227

  18. Jacobs E, Dalhoff A, Brunner H. Efficacy of BAY 12-8039 in Mycoplasma pneumoniae infected guinea pigs [abstract]. 36th ICAAC; 1996 Sep 15; New Orleans, 102

  19. Rouse MS, Piper KE, Patel R, et al. In vitro and in vivo activity of BAY12-8039 or trovafloxacin against penicillin-resistant Streptococcus pneumoniae experimental pneumonia in immunocompetent mice [abstract]. 36th ICAAC 1996 Sep 15; New Orleans: 29

  20. Waterbury K, Wang JJ, Barbiero M, et al. Efficacy of BAY 12-8039, a potent new quinolone, in mouse models of typical and atypical respiratory infection [abstract]. 36th ICAAC 1996 Sep 15; New Orleans: 103

  21. Miyazaki E, Chaisson RE, Bishai WR. In vivo activity of B AY12-8039, a new 8-methoxy-quinolone, in a mouse model of tuberculosis [abstract]. 38th ICAAC 1998; Sep 24; San Diego: 230

  22. Schmidt H, Dalhoff A, Stuertz K, et al. Moxifloxacin in the therapy of experimental pneumococcal meningitis. Antimicrob Agents Chemother 1998 Jun; 42: 1397–401

    PubMed  CAS  Google Scholar 

  23. Ostergaard C, Sorensen TK, Knudsen JD, et al. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant Pneumococcus in rabbits. Antimicrob Agents Chemother 1998 Jul; 42: 1706–12

    PubMed  CAS  Google Scholar 

  24. Dalhoff A. Dissociated resistance among quinolones. Poster presented at ICIDs 1998; May 15–18; Boston

  25. Souli M, Wennersten CB, Eliopoulos GM. In vitro activity of BAY 12-8039, a new fluoroquinolone against species representative of respiratory tract pathogens. Int J Antimicrob Agents 1998; 10(1): 23–30

    Article  PubMed  CAS  Google Scholar 

  26. Tankovic J, Bechoual R, Leclercq L, et al. In vitro activity of BAY 12-8039 against fluoroquinolone-resistant Gram negative bacilli and Enterococcus faecalis. Poster presented at the 37th ICAAC; 1997 Sep 28; Toronto, 169

  27. Schmitz F-J, Hofmann B, Hansen B, et al. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in gr1A, gr1B, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998 Apr; 41: 481–4

    Article  PubMed  CAS  Google Scholar 

  28. Dalhoff A, Heidtmann M, Obertegger S, et al. Lack of in vivo emergence of resistance against BAY 12-08039 in Staph. aureus and Strep pneumoniae [abstract]. 8th ICIDs 1998; May 15: 124

    Google Scholar 

  29. Stass H, Dalhoff A, Kubitza D, et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998 Aug; 42: 2060–5

    PubMed  CAS  Google Scholar 

  30. Sullivan JT, Woodruff M, Lettieri J, et al. Pharmacokinetics (PK) and tolerability of the new methoxyquinolone BAY 12-8039: 10 days’ treatment at 400 mg daily. Poster presented at the 8th ECCMID; 1997 25 May; Lausanne, 4

  31. Stass HH, Kubitza D. Cross over study to assess absolute bioavailability (AB) and absorption characteristics (AC) of moxifloxacin in man. Poster presented at the 8th ICIDs; 1998 May 15–18; Boston

  32. Stass H, Brunner M, Eichler HG, et al. Comparison of skin blister fluid (SBF) and interstitial tissue kinetics of BAY 12-8039 in healthy volunteers (HV) using microdialysis (Mi) [abstract]. 38th ICAAC; 1998 Sep 24; San Diego, 4

  33. Stass H, Kubitza D. Study to assess the interaction between moxifloxacin (M) and dairy products (DP) in healthy volunteers (HV). Poster presented at the 2nd European Congress of Chemotherapy and 7th Biennial Conference of Antiinefective Agents and Chemotherapy, May 10–13, 1998, Hamburg

  34. Andrews J, Honeybourne D, Jevons G, et al. Penetration of Bay 12-8039 into bronchial mucosa, epithelial lining [abstract]. 38th ICAAC; 1998 Sep, San Diego 24, 9

  35. Gehanno P, Stass H, Arvis P. Penetration of moxifloxacin (MFX) into sinus tissues following multiple oral dosing. Abstract accepted by 9th ECCMID; 1999 Mar 21–24; Berlin

  36. Siefert HM, Daehler HP, Goeller G, et al. BAY 12-8039, a new 8-methoxyquinolone: investigations on distribution in rats [abstract]. 37th ICAA; 1997 Sep 28; Toronto, 171

  37. Siefert HM, Bühner K, Domdey-Bette A, et al. BAY 12-8039, a new 8-methoxy-quinolone: pharmacokinetics in rats and monkeys [abstract]. 36th ICAAC 1996 Sep 15; New Orleans: 103

  38. Data on file, Bayer.

  39. Kern A, Kanhai W, Fröhde R, et al. BAY 12-8039, a new 8-methoxy-quinolone: metabolism in rat, monkey, and man [abstract]. 36th ICAAC; 1996 Sep 15; New Orleans, 103

  40. Kubitza D, Stass HH, Wingender W, et al. BAY 12-8039 (I), a new 8-methoxy-quinolone: safety (S), tolerability and steady state pharmacokinetics (PK) in healthy male volunteers [abstract]. 36th ICAAC; 1996 Sep 15; New Orleans, 104

  41. Sullivan JT, Lettieri J, Hogan CH, et al. Age and gender effects on pharmacokinetics (PK) of BAY 12-8039 [abstract]. 98th American Society for Clinical Pharmacology and Therapeutics; 1997 Mar 5; San Diego, 148

  42. Stass H, Halabi A, Delesen H. No dose adjustment needed for patients with renal impairment receiving oral BAY 12-8039 (M) [abstract]. 38th ICAAC; 1998 Sep 24; San Diego, 5

  43. Data on file, Bayer.

  44. Petipretz P, Branco Pires J, Dosedel J, et al. Moxifloxacin (MFX) versus amoxicillin (AMOX) in the treatment of community-acquired suspected pneumococcal pneumonia: a multinational double-blind randomised study. Abstract accepted by 9th ECCMID; 1999 Mar 21–24; Berlin

  45. Krasemann C, Meyer JM, Springkslee M. Moxifloxacin (MFX) in community-acquired pneumonia - a bacteriological and clinical meta-analysis. Poster (#PO205) accepted by 9th ECCMID; 1999 Mar 21–24, Berlin

  46. Wilson R, Kubin R. Short-course moxifloxacin (MFX) vs clarithromycin (CLAR) in acute exacerbations of chronic bronchitis (AECB). Poster (#PO209) accepted by 9th ECCMID; 1999 Mar 21–24; Berlin

  47. Krasemann C, Meyer JM, Springsklee M. Moxifloxacin (MFX) in acute exacerbations of chronic bronchitis - a bacteriological and clinical meta-analysis. Poster (#PO203) accepted by 9th ECCMID; 1999 Mar 21–24; Berlin

  48. Siegert R, Gehanno P, Nikolaidis P, et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. Bayer, data on file

  49. Krasemann C, Meyer JM, Springsklee M. Moxifloxacin in acute sinusitis - a bacteriological and clinical meta-analysis. Poster (#PO204) accepted by 9th ECCMID; 1999 Mar 21–29; Berlin

  50. Springsklee M, Reiter C, Meyer JM. Safety and tolerability profile of MFX. Poster (#PO208) accepted by 9th ECCMID; 1999 Mar 21–29; Berlin

  51. Sullivan JT, Kubitza D, Schuhly U, et al. Safety of the new quinolone BAY 12-8039 in 130 healthy volunteers [abstract]. 20th ICC; 1997 Jun 29; Sydney, 108

  52. Schmuck G, Schurmann A, Schluter G. Determination of the excitatory potency of different fluoroquinolones in the central nervous system by an in vitro model. Antimicrobial Agents and Chemotherapy 1997; 42: 1831–6

    Google Scholar 

  53. Ferguson J, Al-Ajmi H, Kubin R, et al. A double-blind, placebo and lomefloxacin controlled human volunteer phototest study to determine the photosensitising potential of oral moxifloxacin (BAY 12-8039) [abstract]. 8th ICID 1998; 15 May, Boston, 197

  54. Vohr H–W, Wasinska-Kempka G, Ahr HJ. Studies on the phototoxic potential of a new 8-methoxy-quinolone: BAY 12-8039 [abstract]. 36th ICAAC 1996 Sep 15; New Orleans: 103

  55. Stass HH, Boettcher M, Horstmann R. Study to evaluate the interaction between BAY 12-8039 (BA) and antacids (AN) [abstract no. 3358]. 20th ICC; 1997 Jun 29–Jul 3, Sydney, 109

  56. Stass H, Kubitza D. Study to evaluate the interaction between moxifloxacin (M) and iron supplements (FE) [abstract no. T154]. 2nd European Congress of Chemotherapy and 7th Biennial Conference on Antiinfective Agents and Chemotherapy; 1998 May 10-13, Hamburg

  57. Stass HH, Kubitza D, Schwietert R, et al. BAY 12-8039 (BA) does not interact with theophylline (TH) [abstract no. 3356]. 20th ICC, Jun 29–Jul 3, 1997, Sydney: 108

  58. Stass HH, Dietrich H, Sachse R. Influence of a four-times dosing of 500 mg probenecid on kinetics of BAY 12-8039 after administration of a single 400 mg dose in healthy male volunteers [abstract no. F-154]. 37th ICAAC; 1997 28 Sep, Toronto: 172

  59. Stass HH, Ochmann K. Study to evaluate the interaction between BAY 12-8039 (BA) and ranitidine (RA) [abstract no. 3357]. 20th ICC; 1997 Jun 29–Jul 3; Sydney, 108

  60. Müller FO, Hundt HKL, Muir AR, et al. Study to investigate the influence of 400 mg BAY 12-8039 given once daily to healthy volunteers on PK and PD of warfarin (W) [abstract]. 38th ICAAC; 1998 Sep 24; San Diego, 4

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Julia A. Barman Balfour & Lynda R. Wiseman

Authors
  1. Julia A. Barman Balfour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lynda R. Wiseman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julia A. Barman Balfour.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Balfour, J.A.B., Wiseman, L.R. Moxifloxacin. Drugs 57, 363–373 (1999). https://doi.org/10.2165/00003495-199957030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199957030-00007

Keywords

Search

Navigation